China Pharma Holdings, Inc. (AMEX: CPHI) Stock Competitors & Peer Comparison
See CPHI's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CPHI and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CPHI | $0.57 | +7.53% | 24.3M | -1.31 | -$0.43 | N/A |
| TAK | $21.02 | -0.80% | 65.8B | 15.11 | $1.39 | +3.36% |
| TEVA | $42.61 | +1.99% | 49.6B | 14.54 | $2.93 | N/A |
| HLN | $9.14 | -0.11% | 40.2B | 18.69 | $0.49 | +2.18% |
| ZTS | $79.40 | -3.30% | 32.8B | 12.07 | $6.58 | +2.66% |
| VTRS | $19.91 | +4.96% | 22.9B | 7.90 | $2.52 | +2.44% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $25.74 | +8.70% | 12.8B | 24.26 | $1.06 | N/A |
| RDY | $14.91 | +2.62% | 12.4B | 31.71 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
CPHI vs TAK Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TAK has a market cap of 65.8B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TAK trades at $21.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TAK's P/E ratio is 15.11. In terms of profitability, CPHI's ROE is -0.17%, compared to TAK's ROE of +0.05%. Regarding short-term risk, CPHI is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
CPHI vs TEVA Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TEVA has a market cap of 49.6B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TEVA trades at $42.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TEVA's P/E ratio is 14.54. In terms of profitability, CPHI's ROE is -0.17%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, CPHI is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TEVA's competition here
Haleon plc (NYSE: HLN)
CPHI vs HLN Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, HLN has a market cap of 40.2B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while HLN trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas HLN's P/E ratio is 18.69. In terms of profitability, CPHI's ROE is -0.17%, compared to HLN's ROE of +0.10%. Regarding short-term risk, CPHI is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
CPHI vs ZTS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ZTS trades at $79.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ZTS's P/E ratio is 12.07. In terms of profitability, CPHI's ROE is -0.17%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, CPHI is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
CPHI vs VTRS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, VTRS has a market cap of 22.9B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while VTRS trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas VTRS's P/E ratio is 7.90. In terms of profitability, CPHI's ROE is -0.17%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, CPHI is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
CPHI vs ITCI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CPHI's ROE is -0.17%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CPHI is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
CPHI vs ELAN Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ELAN has a market cap of 12.8B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ELAN trades at $25.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ELAN's P/E ratio is 24.26. In terms of profitability, CPHI's ROE is -0.17%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, CPHI is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
CPHI vs RDY Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while RDY trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas RDY's P/E ratio is 31.71. In terms of profitability, CPHI's ROE is -0.17%, compared to RDY's ROE of +0.07%. Regarding short-term risk, CPHI is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
CPHI vs CTLT Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CPHI's ROE is -0.17%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CPHI is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
CPHI vs ALKS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ALKS trades at $45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ALKS's P/E ratio is 48.34. In terms of profitability, CPHI's ROE is -0.17%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, CPHI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
CPHI vs AMRX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AMRX has a market cap of 7B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AMRX trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AMRX's P/E ratio is 22.37. In terms of profitability, CPHI's ROE is -0.17%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, CPHI is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
CPHI vs LNTH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while LNTH trades at $100.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas LNTH's P/E ratio is 16.91. In terms of profitability, CPHI's ROE is -0.17%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, CPHI is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
CPHI vs INDV Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas INDV's P/E ratio is 9.94. In terms of profitability, CPHI's ROE is -0.17%, compared to INDV's ROE of -3.53%. Regarding short-term risk, CPHI is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
CPHI vs BHC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while BHC trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas BHC's P/E ratio is 2.09. In terms of profitability, CPHI's ROE is -0.17%, compared to BHC's ROE of +0.59%. Regarding short-term risk, CPHI is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
CPHI vs HCM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while HCM trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas HCM's P/E ratio is 147.29. In terms of profitability, CPHI's ROE is -0.17%, compared to HCM's ROE of +0.01%. Regarding short-term risk, CPHI is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HCM's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
CPHI vs RGC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while RGC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas RGC's P/E ratio is -531.50. In terms of profitability, CPHI's ROE is -0.17%, compared to RGC's ROE of -1.61%. Regarding short-term risk, CPHI is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check RGC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
CPHI vs DCPH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CPHI's ROE is -0.17%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CPHI is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DCPH's competition here
Perrigo Company plc (NYSE: PRGO)
CPHI vs PRGO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PRGO trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PRGO's P/E ratio is 6.34. In terms of profitability, CPHI's ROE is -0.17%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, CPHI is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PRGO's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
CPHI vs AVDL Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CPHI's ROE is -0.17%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, CPHI is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
CPHI vs TRLV Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TRLV trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TRLV's P/E ratio is -4.69. In terms of profitability, CPHI's ROE is -0.17%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, CPHI is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
CPHI vs EMBCV Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CPHI's ROE is -0.17%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, CPHI is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
CPHI vs DVAX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CPHI's ROE is -0.17%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, CPHI is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
CPHI vs ALVO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ALVO trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ALVO's P/E ratio is -8.15. In terms of profitability, CPHI's ROE is -0.17%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, CPHI is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALVO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
CPHI vs TARO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TARO's P/E ratio is 30.05. In terms of profitability, CPHI's ROE is -0.17%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CPHI is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TARO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
CPHI vs ETON Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ETON trades at $56.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ETON's P/E ratio is 148.58. In terms of profitability, CPHI's ROE is -0.17%, compared to ETON's ROE of +1.05%. Regarding short-term risk, CPHI is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
CPHI vs ANIP Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ANIP has a market cap of 1.5B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ANIP trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ANIP's P/E ratio is 8.20. In terms of profitability, CPHI's ROE is -0.17%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, CPHI is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ANIP's competition here
Supernus, Inc. (NASDAQ: SUPN)
CPHI vs SUPN Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SUPN has a market cap of 1.5B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SUPN trades at $26.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SUPN's P/E ratio is -34.55. In terms of profitability, CPHI's ROE is -0.17%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, CPHI is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SUPN's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
CPHI vs PCRX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PCRX trades at $36.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PCRX's P/E ratio is 14.01. In terms of profitability, CPHI's ROE is -0.17%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, CPHI is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
CPHI vs PAHC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PAHC trades at $32.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PAHC's P/E ratio is 11.25. In terms of profitability, CPHI's ROE is -0.17%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, CPHI is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
CPHI vs CRON Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CRON trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CRON's P/E ratio is 18.51. In terms of profitability, CPHI's ROE is -0.17%, compared to CRON's ROE of +0.05%. Regarding short-term risk, CPHI is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CRON's competition here
Alvotech (NASDAQ: ALVOW)
CPHI vs ALVOW Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ALVOW has a market cap of 1.3B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ALVOW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ALVOW's P/E ratio is 20.44. In terms of profitability, CPHI's ROE is -0.17%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, CPHI is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALVOW's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
CPHI vs AMPH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AMPH trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AMPH's P/E ratio is 9.72. In terms of profitability, CPHI's ROE is -0.17%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, CPHI is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
CPHI vs HROW Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while HROW trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas HROW's P/E ratio is -27.19. In terms of profitability, CPHI's ROE is -0.17%, compared to HROW's ROE of -1.04%. Regarding short-term risk, CPHI is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
CPHI vs PETQ Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CPHI's ROE is -0.17%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CPHI is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
CPHI vs COLL Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, COLL has a market cap of 787.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while COLL trades at $24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas COLL's P/E ratio is 3.04. In terms of profitability, CPHI's ROE is -0.17%, compared to COLL's ROE of +0.12%. Regarding short-term risk, CPHI is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
CPHI vs IRWD Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, IRWD has a market cap of 725.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while IRWD trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas IRWD's P/E ratio is 5.63. In terms of profitability, CPHI's ROE is -0.17%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, CPHI is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
CPHI vs EVO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas EVO's P/E ratio is -2.39. In terms of profitability, CPHI's ROE is -0.17%, compared to EVO's ROE of -0.27%. Regarding short-term risk, CPHI is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
CPHI vs BDSI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CPHI's ROE is -0.17%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CPHI is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
CPHI vs TKNO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TKNO has a market cap of 481.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TKNO trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TKNO's P/E ratio is -25.19. In terms of profitability, CPHI's ROE is -0.17%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, CPHI is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
CPHI vs EOLS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, EOLS has a market cap of 452.8M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while EOLS trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas EOLS's P/E ratio is -21.71. In terms of profitability, CPHI's ROE is -0.17%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, CPHI is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
CPHI vs AQST Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AQST has a market cap of 452.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AQST trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AQST's P/E ratio is -5.54. In terms of profitability, CPHI's ROE is -0.17%, compared to AQST's ROE of +2.55%. Regarding short-term risk, CPHI is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
CPHI vs KMDA Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, KMDA has a market cap of 416.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while KMDA trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas KMDA's P/E ratio is 19.00. In terms of profitability, CPHI's ROE is -0.17%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CPHI is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check KMDA's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
CPHI vs ACB Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ACB has a market cap of 331.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ACB trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ACB's P/E ratio is -3.78. In terms of profitability, CPHI's ROE is -0.17%, compared to ACB's ROE of -0.21%. Regarding short-term risk, CPHI is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ACB's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
CPHI vs TLRY Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TLRY has a market cap of 326.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TLRY trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TLRY's P/E ratio is -2.09. In terms of profitability, CPHI's ROE is -0.17%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, CPHI is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
CPHI vs EBS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, EBS has a market cap of 309.7M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while EBS trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas EBS's P/E ratio is 4.19. In terms of profitability, CPHI's ROE is -0.17%, compared to EBS's ROE of -0.61%. Regarding short-term risk, CPHI is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
CPHI vs ALIM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CPHI's ROE is -0.17%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CPHI is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ALIM's competition here
Canopy Growth Corporation (NASDAQ: CGC)
CPHI vs CGC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CGC has a market cap of 275.8M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CGC trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CGC's P/E ratio is -1.46. In terms of profitability, CPHI's ROE is -0.17%, compared to CGC's ROE of -0.37%. Regarding short-term risk, CPHI is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CGC's competition here
Landec Corporation (NASDAQ: LNDC)
CPHI vs LNDC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CPHI's ROE is -0.17%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, CPHI is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check LNDC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
CPHI vs LFCR Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, LFCR has a market cap of 241.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while LFCR trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas LFCR's P/E ratio is -5.01. In terms of profitability, CPHI's ROE is -0.17%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, CPHI is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
CPHI vs TYHT Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CPHI's ROE is -0.17%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CPHI is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
CPHI vs SIGA Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SIGA has a market cap of 223.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SIGA trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SIGA's P/E ratio is 11.52. In terms of profitability, CPHI's ROE is -0.17%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, CPHI is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
CPHI vs GLAS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, GLAS has a market cap of 182.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while GLAS trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas GLAS's P/E ratio is -3.71. In terms of profitability, CPHI's ROE is -0.17%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, CPHI is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
CPHI vs REPH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas REPH's P/E ratio is -8.04. In terms of profitability, CPHI's ROE is -0.17%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CPHI is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
CPHI vs THTX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas THTX's P/E ratio is -28.83. In terms of profitability, CPHI's ROE is -0.17%, compared to THTX's ROE of +0.36%. Regarding short-term risk, CPHI is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
CPHI vs ASRT Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ASRT's P/E ratio is -7.10. In terms of profitability, CPHI's ROE is -0.17%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CPHI is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
CPHI vs DERM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, DERM has a market cap of 126.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while DERM trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas DERM's P/E ratio is -20.36. In terms of profitability, CPHI's ROE is -0.17%, compared to DERM's ROE of -0.20%. Regarding short-term risk, CPHI is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
CPHI vs OGI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, OGI has a market cap of 123.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while OGI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas OGI's P/E ratio is 1.97. In terms of profitability, CPHI's ROE is -0.17%, compared to OGI's ROE of +0.21%. Regarding short-term risk, CPHI is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
CPHI vs CRDL Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CRDL has a market cap of 119.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CRDL trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CRDL's P/E ratio is -3.94. In terms of profitability, CPHI's ROE is -0.17%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, CPHI is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CRDL's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
CPHI vs SCTL Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CPHI's ROE is -0.17%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CPHI is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
CPHI vs BGM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, BGM has a market cap of 111.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while BGM trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas BGM's P/E ratio is -1.83. In terms of profitability, CPHI's ROE is -0.17%, compared to BGM's ROE of -0.05%. Regarding short-term risk, CPHI is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check BGM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
CPHI vs ORGO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ORGO has a market cap of 104.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ORGO trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ORGO's P/E ratio is 27.11. In terms of profitability, CPHI's ROE is -0.17%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, CPHI is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ORGO's competition here
Procaps Group S.A. (NASDAQ: PROC)
CPHI vs PROC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PROC's P/E ratio is 1.53. In terms of profitability, CPHI's ROE is -0.17%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CPHI is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
CPHI vs OPTN Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CPHI's ROE is -0.17%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, CPHI is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
CPHI vs ZOM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CPHI's ROE is -0.17%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, CPHI is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
CPHI vs GRVI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CPHI's ROE is -0.17%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, CPHI is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check GRVI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
CPHI vs CPIX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CPIX has a market cap of 78.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CPIX trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CPIX's P/E ratio is -13.02. In terms of profitability, CPHI's ROE is -0.17%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, CPHI is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CPIX's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
CPHI vs ZYBT Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ZYBT trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, CPHI's ROE is -0.17%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, CPHI is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
CPHI vs ZYNE Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CPHI's ROE is -0.17%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CPHI is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
CPHI vs SSIC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CPHI's ROE is -0.17%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CPHI is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
CPHI vs VLNS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CPHI's ROE is -0.17%, compared to VLNS's ROE of N/A. Regarding short-term risk, CPHI is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
CPHI vs DRRX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CPHI's ROE is -0.17%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, CPHI is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
CPHI vs TLPH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TLPH has a market cap of 55M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TLPH's P/E ratio is -3.93. In terms of profitability, CPHI's ROE is -0.17%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, CPHI is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check TLPH's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
CPHI vs JUPW Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CPHI's ROE is -0.17%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, CPHI is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check JUPW's competition here
InterCure Ltd. (NASDAQ: INCR)
CPHI vs INCR Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, INCR has a market cap of 39.7M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while INCR trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas INCR's P/E ratio is -3.53. In terms of profitability, CPHI's ROE is -0.17%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CPHI is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check INCR's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
CPHI vs QLI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas QLI's P/E ratio is -4.92. In terms of profitability, CPHI's ROE is -0.17%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CPHI is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
CPHI vs RMTI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, RMTI has a market cap of 31.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while RMTI trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas RMTI's P/E ratio is -5.79. In terms of profitability, CPHI's ROE is -0.17%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, CPHI is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
CPHI vs HEXO Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CPHI's ROE is -0.17%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CPHI is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check HEXO's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
CPHI vs SHPH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SHPH has a market cap of 25.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SHPH trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SHPH's P/E ratio is -0.25. In terms of profitability, CPHI's ROE is -0.17%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, CPHI is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
CPHI vs CYTH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CPHI's ROE is -0.17%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, CPHI is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check CYTH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
CPHI vs TXMD Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, TXMD has a market cap of 19.7M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while TXMD trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas TXMD's P/E ratio is 86.60. In terms of profitability, CPHI's ROE is -0.17%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, CPHI is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
CPHI vs AYTU Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AYTU has a market cap of 19.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AYTU trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AYTU's P/E ratio is -1.52. In terms of profitability, CPHI's ROE is -0.17%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, CPHI is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
CPHI vs EVOK Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CPHI's ROE is -0.17%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, CPHI is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
CPHI vs ACRX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CPHI's ROE is -0.17%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, CPHI is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
CPHI vs OPTH Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, OPTH has a market cap of 12.9M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while OPTH trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas OPTH's P/E ratio is -1.45. In terms of profitability, CPHI's ROE is -0.17%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, CPHI is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
CPHI vs AGRX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CPHI's ROE is -0.17%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CPHI is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
CPHI vs CABR Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, CABR has a market cap of 9.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while CABR trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas CABR's P/E ratio is -1.32. In terms of profitability, CPHI's ROE is -0.17%, compared to CABR's ROE of -3.86%. Regarding short-term risk, CPHI is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check CABR's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
CPHI vs NLTX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CPHI's ROE is -0.17%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CPHI is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
CPHI vs INM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, INM has a market cap of 8.1M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas INM's P/E ratio is -4.80. In terms of profitability, CPHI's ROE is -0.17%, compared to INM's ROE of -2.64%. Regarding short-term risk, CPHI is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
CPHI vs LCI Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas LCI's P/E ratio is -0.04. In terms of profitability, CPHI's ROE is -0.17%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CPHI is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
CPHI vs ADMP Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CPHI's ROE is -0.17%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CPHI is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ADMP's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
CPHI vs SBFM Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SBFM trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SBFM's P/E ratio is -0.45. In terms of profitability, CPHI's ROE is -0.17%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, CPHI is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SBFM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
CPHI vs SNOA Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SNOA has a market cap of 5.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SNOA trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SNOA's P/E ratio is -1.00. In terms of profitability, CPHI's ROE is -0.17%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, CPHI is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
CPHI vs MNK Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas MNK's P/E ratio is -0.44. In terms of profitability, CPHI's ROE is -0.17%, compared to MNK's ROE of -0.36%. Regarding short-term risk, CPHI is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
CPHI vs YCBD Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, YCBD has a market cap of 4.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while YCBD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas YCBD's P/E ratio is -0.99. In terms of profitability, CPHI's ROE is -0.17%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CPHI is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
CPHI vs FLGC Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CPHI's ROE is -0.17%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, CPHI is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
CPHI vs SBFMW Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas SBFMW's P/E ratio is N/A. In terms of profitability, CPHI's ROE is -0.17%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, CPHI is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
CPHI vs GELS Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, GELS has a market cap of 4M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while GELS trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas GELS's P/E ratio is -1.00. In terms of profitability, CPHI's ROE is -0.17%, compared to GELS's ROE of -0.36%. Regarding short-term risk, CPHI is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
CPHI vs PLXP Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CPHI's ROE is -0.17%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CPHI is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for CPHI.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
CPHI vs ATNX Comparison November 2026
China Pharma Holdings, Inc. (AMEX: CPHI) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPHI stands at 24.3M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CPHI is priced at $0.57 on the AMEX, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPHI currently has a P/E ratio of -1.31, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CPHI's ROE is -0.17%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CPHI is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for CPHI.Check ATNX's competition here